ArticleCell reports. Medicine2024
Modeling lung adenocarcinoma metastases using patient-derived organoids.
Abstract read
In one paragraph
Article in Cell reports. Medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- [Organoid-based strategies and challenges in tissue regeneration].Zhonghua shao shang yu chuang mian xiu fu za zhi · 2026Pooled it
- Advancing lung organoids toward clinical applications: a global perspective on research focus and future directions.Frontiers in medicine · 2025Pooled it
- Shengxian decoction suppresses malignant progression of lung adenocarcinoma by enhancing CD8Chinese medicine · 2026Article
- Deconstructing cancer in 3D: models, mechanisms, and personalized solutions.Molecular cancer · 2026Review
- Cell-type Specific Alteration ofbioRxiv : the preprint server for biology · 2026Article
- Application of organoid models in basic and translational research of lung cancer: a narrative review.Translational lung cancer research · 2026Review
- Patient-Derived Lung Cancer Organoids for Precision Oncology: A Comprehensive Analysis.JTO clinical and research reports · 2026Article
- Organoids in Cancer Research and Regenerative Medicine: Current Status, Challenges, and Future Prospects.MedComm · 2026Review
- Lung cancer organoids for functional precision oncology: from disease modeling to clinical decision support.Frontiers in oncology · 2026Review
- Article
- Personalized prediction of chemotherapy efficacy in osteosarcoma through patient-derived organoids: correlation with survival and tumor proliferation potential.Journal of experimental & clinical cancer research : CR · 2025Article
- Synergistic targeting strategies for prostate cancer.Nature reviews. Urology · 2025Review
- Identification of metabolic driver genes and targeted drug screening for lung adenocarcinoma metastasis at the single-cell resolution.Translational cancer research · 2025Article
- EMP3 is upregulated upon epithelial-mesenchymal transition and contributes to EGFR-tyrosine kinase inhibitor resistance in lung adenocarcinoma.European journal of medical research · 2025Article
- Construction of lung adenocarcinoma subtype and prognosis model based on fatty acid metabolism-related genes.Discover oncology · 2025Article
- Immunotherapy in lung cancer brain metastases.NPJ precision oncology · 2025Review
- Tumor organoid-immune co-culture models: exploring a new perspective of tumor immunity.Cell death discovery · 2025Review
- Lung cancer organoids: a new strategy for precision medicine research.Translational lung cancer research · 2025Review
- Airway Organoid Models as Pivotal Tools for Unraveling Molecular Mechanisms and Therapeutic Targets in Respiratory Diseases: A Literature Review.Therapeutics and clinical risk management · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Yuan LiuThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Fiona and Stanley Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Manendra LankadasariThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Fiona and Stanley Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Joel RosieneDepartment of Pathology, New York University, New York, NY, USA.
Kofi E JohnsonMeyer Cancer Center, Weill Cornell Medicine, New York, NY, USA; Tri-Institutional PhD Program in Computational Biology and Medicine, New York, NY, USA.
Juan ZhouThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Fiona and Stanley Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Samhita BapatThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Fiona and Stanley Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Lai-Fong L Chow-TsangThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Fiona and Stanley Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Huasong TianDepartment of Pathology, New York University, New York, NY, USA.
Brooke MastrogiacomoThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Fiona and Stanley Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Computational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Di HeThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Fiona and Stanley Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
James G ConnollyThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Fiona and Stanley Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Harry B LengelThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Fiona and Stanley Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Raul CasoThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Fiona and Stanley Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Elizabeth G DunneThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Fiona and Stanley Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Cameron N FickThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Fiona and Stanley Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Gaetano RoccoThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Fiona and Stanley Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Smita SihagThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Fiona and Stanley Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
James M IsbellThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Fiona and Stanley Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mathew J BottThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Fiona and Stanley Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Bob T LiFiona and Stanley Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Piro LitoFiona and Stanley Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Cameron W BrennanDepartment of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mark H BilskyDepartment of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Natasha RekhtmanFiona and Stanley Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Prasad S AdusumilliThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Fiona and Stanley Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Marty W MayoDepartment of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA, USA.
Marcin ImielinskiDepartment of Pathology, New York University, New York, NY, USA.
David R JonesThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Fiona and Stanley Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: jonesd2@mskcc.org.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MCell-of-Origin Footprints of Passenger Mutations in Human Lung CancerR37CA229861 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Marcin Imielinski · 2021 to 2026
$3.2MTargeting the ROR2/p-GSK3bS9 pathway to suppress metastasis in SMARCA4-deficient lung adenocarcinomaR01CA285856 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI David R Jones · 2024 to 2026
$2.7MBRMS1-mediated suppression of metastases in p53 mutant lung adenocarcinomaR01CA217169 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI JONES, DAVID R · 2018 to 2022
$2.5MTargeting SNP BRMS1v2 A273V/A273V to reduce metastases in lung adenocarcinomaR01CA240472 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI JONES, DAVID R · 2019 to 2023
$2.4MIdentifying tumor suppressor targets of SIRT6 in lung cancerR01CA192399 · NCI · UNIVERSITY OF VIRGINIA · PI MAYO, MARTY W · 2015 to 2019
$1.9MNCI NIH HHS P30 CA008748NCI NIH HHS R01 CA192399NCI NIH HHS R01 CA217169NCI NIH HHS R01 CA240472NCI NIH HHS R01 CA285856NCI NIH HHS R37 CA229861
Abstract
Approximately 50% of patients with surgically resected early-stage lung cancer develop distant metastasis. At present, there is no in vivo metastasis model to investigate the biology of human lung cancer metastases. Using well-characterized lung adenocarcinoma (LUAD) patient-derived organoids (PDOs), we establish an in vivo metastasis model that preserves the biologic features of human metastases. Results of whole-genome and RNA sequencing establish that our in vivo PDO metastasis model can be used to study clonality and tumor evolution and to identify biomarkers related to organotropism. Investigation of the response of KRAS
Indexed as
Adenocarcinoma of LungLung NeoplasmsOrganoidsAnimalsHumansLeukocytes, MononuclearMiceModels, BiologicalNeoplasm MetastasisProto-Oncogene Proteins p21(ras)Proto-Oncogene Proteins p21(ras)coculturedrug resistanceimmune primingin vivo LUAD metastasislung adenocarcinomametastasis markerpatient-derived organoidstumor evolution
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.